Category
PHS Pricing Under Pressure: Managing Duplicate Discounts and Diversion Risks in 2025
Duplicate discounts and diversion are two of the most persistent risks in pharmaceutical pricing, and in 2025, they’re under the microscope. HRSA audits are tougher, state-level carve-in/carve-out rules are more complex, and manufacturers are expected to prove not only that they have controls in place, but that those controls are… Read More
HRSA Launches 340B Rebate Model Pilot Program: What Manufacturers Need to Know
The Health Resources and Services Administration (HRSA) has introduced a significant new development for the 340B Drug Pricing Program with the launch of its 340B Rebate Model Pilot Program. This initiative offers drug manufacturers a fresh, alternative pathway to comply with their 340B pricing obligations, aimed at addressing longstanding industry… Read More
Live Webinar: Modernizing Customer Class of Trade Management: Best Practices for Clean Segmentation & Contracting
Join us for a live webinar hosted by Sarah McClure, VP of Knowledge Management Date: July 15, 2025 Time: 2:00 PM ET Special Guests: To be announced! Why Attend? Channel complexity is increasing- IDNs, specialty pharmacies, and 340B entities are reshaping the landscape. Getting your Class of Trade… Read More